Hansa Biopharma Taps Cradle's AI Platform to Advance Autoimmune Disease Drug Discovery

05:42 AM EDT, 10/01/2026 (MT Newswires) -- Hansa Biopharma (HNSA.ST) is teaming up with Cradle to deploy end-to-end artificial intelligence technology across its drug discovery pipeline. The commercial-stage biopharmaceutical company will use Cradle's AI-powered protein design and engineering platform for biologics to develop new immunomodulatory therapies for rare and severe autoimmune diseases, according to a Thursday release.